专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明授权

US08128933B2 Method of promoting bone growth by an anti-activin B antibody 有权
标题翻译：通过抗激活素B抗体促进骨生长的方法
公开(公告)号：US08128933B2
公开(公告)日：2012-03-06
申请号：US12387788
申请日：2009-05-06
申请人： John Knopf , Jasbir Seehra
发明人： John Knopf , Jasbir Seehra
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： C07K16/22 , A61K38/00 , A61K38/179 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/575 , C07K14/71 , C07K2317/76 , C07K2319/30 , C12N15/1136 , C12N15/1138 , C12N2310/11
摘要： In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
摘要翻译：在某些方面，本发明提供用于促进骨生长和增加骨密度的组合物和方法。

92. 发明授权

US08097436B2 Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof 有权
公开(公告)号：US08097436B2
公开(公告)日：2012-01-17
申请号：US12938180
申请日：2010-11-02
申请人： Pablo Umaña , Ekkehard Mössner
发明人： Pablo Umaña , Ekkehard Mössner
IPC分类号： C12P21/06 , C12P21/08 , C12N1/20 , C12N15/00 , C07H21/04 , C07K16/28
CPC分类号： C07K16/2863 , A61K38/179 , A61K45/06 , A61K47/6803 , A61K47/6817 , A61K2039/505 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2319/00
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

93. 发明授权

US08097253B2 Methods for inhibiting angiogenesis 失效
标题翻译：抑制血管发生的方法
公开(公告)号：US08097253B2
公开(公告)日：2012-01-17
申请号：US12271825
申请日：2008-11-14
申请人： Dean Y. Li , Kyle Won Park
发明人： Dean Y. Li , Kyle Won Park
IPC分类号： A61K39/00 , C07K16/00 , C07K16/18
CPC分类号： A61K38/18 , A61K38/179 , A61K38/1825 , A61K38/1858 , A61K38/1866 , A61K38/1891 , A61K2300/00
摘要： The present invention provides methods and compositions for modulating proliferation, differentiation, migration, and adhesion of cardiovascular cell types.
摘要翻译：本发明提供用于调节心血管细胞类型的增殖，分化，迁移和粘附的方法和组合物。

94. 发明授权

US07981863B2 Treatment of Parkinson's disease with PDGF 有权
标题翻译：用PDGF治疗帕金森病
公开(公告)号：US07981863B2
公开(公告)日：2011-07-19
申请号：US10246091
申请日：2002-09-18
申请人： Kioumars Delfani , Ann Marie Janson , H. Georg Kuhn , Karlheinz Plate , Anne Schanzer , Frank-Peter Wachs , Ming Zhao
发明人： Kioumars Delfani , Ann Marie Janson , H. Georg Kuhn , Karlheinz Plate , Anne Schanzer , Frank-Peter Wachs , Ming Zhao
IPC分类号： A61K38/00 , A61K38/18 , C12N5/00 , C12N5/079 , C12N5/0797 , C12N5/0793 , C07K14/49
CPC分类号： A61K38/1858 , A61K35/30 , A61K38/179 , A61K38/1866 , A61K45/06 , A61K48/00 , G01N33/5008 , G01N2333/49 , G01N2333/515 , A61K2300/00
摘要： The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells. These methods are useful for reducing at least one symptom of the disorder.
摘要翻译：本发明一般涉及影响中枢神经系统细胞以产生可用于治疗CNS病症的后代的方法。更具体地，本发明包括将患有这种病症的患者暴露于调节中枢神经系统细胞的增殖，迁移，分化和存活的试剂的方法。这些方法可用于减少至少一种症状。

95. 发明授权

US07960343B2 Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion 有权
标题翻译：活化素-actRIIa拮抗剂和用于降低或抑制FSH分泌的用途
公开(公告)号：US07960343B2
公开(公告)日：2011-06-14
申请号：US12284112
申请日：2008-09-17
申请人： John Knopf , Jasbir Seehra , Matthew L. Sherman
发明人： John Knopf , Jasbir Seehra , Matthew L. Sherman
IPC分类号： A61K38/00
CPC分类号： C12N9/12 , A61K38/179 , C07K14/71 , C07K2319/30 , C12Y207/1103
摘要： In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
摘要翻译：在某些方面，本发明提供用于降低患者中FSH水平的组合物和方法。患者可能例如被诊断患有FSH相关疾病或延迟或抑制生殖细胞成熟的欲望。

96. 发明申请

US20100331252A1 Myostatin inhibitor enhancement of musculoskeletal repair 审中-公开
标题翻译：肌肉抑制素抑制剂增强肌肉骨骼修复
公开(公告)号：US20100331252A1
公开(公告)日：2010-12-30
申请号：US12803413
申请日：2010-06-25
申请人： Mark W. Hamrick
发明人： Mark W. Hamrick
IPC分类号： A61K38/18 , A61K9/14 , A61P19/04
CPC分类号： A61K38/18 , A61K9/0019 , A61K9/0092 , A61K9/06 , A61K9/5153 , A61K38/179 , A61K47/20 , A61K47/42
摘要： The methods and compositions of this invention provide a means of regenerating injured musculoskeletal tissue by inhibition of myostatin function. The invention provides methods of treating a nonunion fracture in an individual comprising delivering to the fracture via a delivery system comprising biodegradable hydrogel, a pharmacological amount of myostatin propeptide effective to inhibit myostatin function. The invention also teaches compositions useful for the treatment of non-union fracture in an individual, said compositions comprising a pharmacological amount of myostatin propeptide effective to inhibit myostatin function; and a delivery system for delivering said myostatin propeptide to said fracture, wherein the delivery system comprises a biodegradable hydrogel or biodegradable nanobeads.
摘要翻译：本发明的方法和组合物提供通过抑制肌生成抑制素功能来再生损伤的肌肉骨骼组织的方法。本发明提供了治疗个体中不连续骨折的方法，包括通过包含可生物降解的水凝胶的递送系统递送至骨折，该药物组合物有效抑制肌生成抑制素功能的药理学量。本发明还教导了可用于治疗个体中非并发骨折的组合物，所述组合物包含有效抑制肌生成抑制素功能的药理学量的肌生成抑制素前肽; 以及用于将所述肌生成抑制素前肽递送到所述骨折的递送系统，其中所述递送系统包括可生物降解的水凝胶或可生物降解的纳米骨。

97. 发明申请

US20100316626A1 METHODS FOR TREATMENT AND DIAGNOSIS OF PSYCHIATRIC DISORDERS 审中-公开
标题翻译：治疗和诊断心理疾病的方法
公开(公告)号：US20100316626A1
公开(公告)日：2010-12-16
申请号：US12377025
申请日：2007-08-10
申请人： Andres Buonanno
发明人： Andres Buonanno
IPC分类号： A61K39/395 , C12Q1/68 , G01N33/53 , A61K38/00 , A61K31/7088 , A61P25/18 , A61P25/00 , A61P25/24
CPC分类号： A61K38/179 , A61K31/517 , A61K31/519 , A61K38/1883 , G01N33/5058 , G01N2800/30 , G01N2800/52
摘要： A method for preventing or treating a psychiatric disorder in a mammalian subject is provided. A method for preventing or treating a psychiatric disorder in a mammalian subject is provided which comprises administering to the subject a modulator of ErbB receptor signaling in an amount effective to reduce or eliminate the psychiatric disorder in the subject or to prevent its occurrence or recurrence. A method for diagnosis of a psychiatric disorder in a mammalian subject is provided.
摘要翻译：提供了一种用于预防或治疗哺乳动物受试者的精神病的方法。提供了一种用于预防或治疗哺乳动物受试者的精神病学障碍的方法，其包括以有效减少或消除受试者的精神病症或防止其发生或复发的方式向受试者施用ErbB受体信号传导调节剂。提供了一种诊断哺乳动物受试者精神障碍的方法。

98. 发明申请

US20100278736A1 FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy 有权
标题翻译： FLT4（VEGFR-3）作为肿瘤成像和抗肿瘤治疗的靶标
公开(公告)号：US20100278736A1
公开(公告)日：2010-11-04
申请号：US12707423
申请日：2010-02-17
申请人： KARI ALITALO , ARJA KAIPAINEN , REJIA VALTOLA , LOLLA JUSSILA
发明人： KARI ALITALO , ARJA KAIPAINEN , REJIA VALTOLA , LOLLA JUSSILA
IPC分类号： A61K49/00 , A61K39/395 , A61K38/45 , G01N33/567 , G01N33/574 , G01N33/573 , A61K38/18
CPC分类号： A61K38/45 , A61K38/179 , A61K38/1866 , A61K39/39558 , A61K48/00 , A61K49/0004 , A61K2039/505 , C07K14/71 , C07K16/28 , C07K2319/30 , C12Y207/10001
摘要： The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
摘要翻译：本发明提供了纯化的Flt4受体酪氨酸激酶多肽及其片段，编码这种多肽的多核苷酸，特异性结合这些多肽的抗体以及用于其的用途。

99. 发明申请

US20100267133A1 ACRTIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS 有权
标题翻译： ACRTIIB-FC多核苷酸，多肽和组合物
公开(公告)号：US20100267133A1
公开(公告)日：2010-10-21
申请号：US12751868
申请日：2010-03-31
申请人： JOHN KNOPF , JASBIR SEEHRA
发明人： JOHN KNOPF , JASBIR SEEHRA
IPC分类号： C12N5/10 , C12N15/12 , C07K2/00
CPC分类号： C12N9/12 , A61K9/2072 , A61K38/179 , A61K38/1796 , A61K38/45 , C07K14/705 , C07K16/00 , C07K2319/30 , C07K2319/32 , C07K2319/70 , C12Y207/1103
摘要： In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
摘要翻译：在某些方面，本发明提供用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪和/或神经元生长的组合物和方法。本发明还提供筛选调节ActRII蛋白和/或ActRII配体的活性的化合物的方法。本文提供的组合物和方法可用于治疗与ActRII蛋白和/或ActRII配体的异常活性相关的疾病。

100. 发明申请

US20100209443A1 Vaccine for the Prevention of Breast Cancer Relapse 有权
标题翻译：疫苗预防乳腺癌复发
公开(公告)号：US20100209443A1
公开(公告)日：2010-08-19
申请号：US12602214
申请日：2008-04-11
申请人： George E. Peoples , Ponniah Sathibalan
发明人： George E. Peoples , Ponniah Sathibalan
IPC分类号： A61K39/00 , A61K38/08 , A61P35/00
CPC分类号： A61K39/0011 , A61K38/179 , A61K38/193 , A61K39/00 , A61K39/39 , A61K2039/545 , A61K2039/55522 , C07K14/71
摘要： The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
摘要翻译：本发明的特征在于诱导和维持对HER2 / neu癌基因E75的肽的保护性细胞毒性T淋巴细胞应答的方法，其具有在临床缓解患者中诱导和维持对乳腺癌的保护性或治疗性免疫的作用。所述方法包括以优化的剂量和时间表向患者施用有效量的包含药学上可接受的载体，佐剂如重组人GM-CSF和E75肽的疫苗组合物。该方法还包括由于E75特异性T细胞免疫力下降而施用一年或半年一次的加强疫苗剂量。本发明还特征在于用于该方法的疫苗组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式